$CRSP
CRISPR Therapeutics AG · NasdaqGM · Healthcare
- Market cap
- 5.39B
- Volume
- 904.3K
- P/E
- -15.95
- Day range
- 55.35 – 57.21
- 52w range
- 44.12 – 78.48
- Analyst target
- 87.56
AI Summary
Generating a unique summary for CRSP…
AI-generated for information only — not investment advice.
Share this ticker
$CRSP -1.24% at 55.79 Cathie Wood and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/CRSP
Company summary
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Institutional ownership
Institutions hold 77.81% · insiders 5.89% · 677 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 9.46M | $527.83M | 9.78% | 2026-06-30 |
| Blackrock Inc. | 8.35M | $465.79M | 8.63% | 2026-06-30 |
| Orbis Allan Gray Ltd | 5.45M | $304.01M | 5.64% | 2026-06-30 |
| Capital World Investors | 4.75M | $264.98M | 4.91% | 2026-06-30 |
| State Street Corporation | 4.32M | $241.11M | 4.47% | 2026-06-30 |
| GSK plc | 3.22M | $179.68M | 3.33% | 2026-06-30 |
| Geode Capital Management, LLC | 2.51M | $140.03M | 2.60% | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 2.05M | $114.54M | 2.12% | 2026-06-30 |
| SR One Capital Management, LP | 2.04M | $113.74M | 2.11% | 2026-06-30 |
| Two Sigma Investments, LP | 1.99M | $110.95M | 2.06% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| PRASAD RAJU | Chief Financial Officer | Stock Gift at price 0.00 per share. | 750.00 | 2026-08-07 |
| PATEL NAIMISH | Officer | Sale at price 55.62 per share. | 3.8K | 2026-05-29 |
| PATEL NAIMISH | Officer | — | 10.0K | 2026-05-28 |
| KULKARNI SAMARTH | Chief Executive Officer | Sale at price 46.78 per share. | 10.0K | 2026-03-23 |
| KASINGER JAMES R. | General Counsel | Sale at price 46.78 per share. | 3.2K | 2026-03-23 |
| PRASAD RAJU | Chief Financial Officer | Sale at price 46.78 per share. | 3.7K | 2026-03-23 |
| PRASAD RAJU | Chief Financial Officer | — | 6.3K | 2026-03-20 |
| KULKARNI SAMARTH | Chief Executive Officer | — | 19.7K | 2026-03-20 |
| KASINGER JAMES R. | General Counsel | — | 6.3K | 2026-03-20 |
| PRASAD RAJU | Chief Financial Officer | Stock Gift at price 0.00 per share. | 750.00 | 2026-03-16 |
| KULKARNI SAMARTH | Chief Executive Officer | Sale at price 48.26 per share. | 10.3K | 2026-03-16 |
| KASINGER JAMES R. | General Counsel | Sale at price 48.26 per share. | 3.5K | 2026-03-16 |
Analyst ratings
Consensus score 2.05 (1 = strong buy, 5 = sell) · mean target 87.56
- CitizensMarket Outperformreit2026-08-31
- NeedhamBuyreit2026-08-31
- CitizensMarket Outperformreit2026-08-25
- CitigroupBuymain2026-08-04
- HC Wainwright & Co.Buyreit2026-07-08
- CitizensMarket Outperformreit2026-07-06
- BernsteinMarket Performmain2026-05-13
- CitigroupBuymain2026-05-06
- Piper SandlerOverweightreit2026-03-17
- Chardan CapitalBuymain2026-02-17
Earnings
Next report: 2026-11-09
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | -1.17 | -1.29 | 0.12 |
| 4Q2025 | -1.37 | -1.23 | -0.14 |
| 1Q2026 | -1.28 | -1.23 | -0.05 |
| 2Q2026 | -0.94 | -1.18 | 0.24 |
SEC filings
- 8-KCorporate Changes & Voting Matters2026-08-03Open
- S-8Offering Registrations2026-06-05Open
- 8-KCorporate Changes & Voting Matters2026-06-04Open
- 10-QPeriodic Financial Reports2026-05-04Open
- ARSAnnual Report to Shareholders2026-04-21Open
- PRE 14AProxy Statements2026-04-02Open
- 8-KCorporate Changes & Voting Matters2026-03-16Open
- 8-KCorporate Changes & Voting Matters2026-03-11Open
- 10-KPeriodic Financial Reports2026-02-12Open
- 8-KCorporate Changes & Voting Matters2026-01-12Open
Latest CRSP news
- 2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
We'll know a little more about the company's prospects by the end of the year.
Wed, 02 Sep 2026 23:05:00 +0000
- CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As CTX310 Data Impresses
CRISPR Therapeutics stock has climbed in the shorter term but still carries a heavy five year loss, and current valuation checks point to a company that does not clearly screen as either cheap or expensive. For investors looking at CRISPR Therapeutics today, the share price near US$56.82 sits against a mixed valuation read and a long term track record that remains in the red. The stock has fallen 52.9% over 5 years, which means long term holders are still under water despite more recent...
Wed, 02 Sep 2026 21:08:11 +0000
- Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wed, 02 Sep 2026 15:30:05 +0000
- CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean reduction in triglycerides (TG) of 48% (maximum 78%), and a mean reduction of low-density lipoprotein (LDL) of 53% (maximum 84%) at the highest dose- -CTX310 was well tolerated with no treatment-related serious
Fri, 28 Aug 2026 14:31:00 +0000
- CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.
Fri, 21 Aug 2026 14:50:00 +0000
- Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says
Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia
Tue, 04 Aug 2026 15:49:54 +0000
- CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
Tue, 04 Aug 2026 14:56:00 +0000
- CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Mon, 03 Aug 2026 22:45:04 +0000